DOCSLIB.ORG

ANALGESIC Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ANALGESIC Drugs ANALGESIC, NSAID, ANTISPASMODIC, ANTIINFLAMMATORY DRUGS SL.NO COMPOSITION STRENGTH 1 Aceclofenac and Paracetamol Tablets 100 mg / 325 mg 2 Aceclofenac Tablets 100 mg 3 Aceclofenac Tablets 200 mg 4 Aceclofenac and Thiocolchicoside Tablets 100 mg / 8 mg 5 Dexibuprofen Tablets 400 mg 6 Diclofenac Potassium and Serratiopeptidase Tablets 50 mg / 10 mg 7 Etodolac and Paracetamol Tablets 300 mg / 325 mg 8 Etodolac Tablets 400 mg 9 Etodolac and Paracetamol Tablets 400 mg / 325 mg 10 Etodolac and Thiocolchicoside Tablets 400 mg / 4 mg 11 Etodolac and Thiocolchicoside Tablets 400 mg / 8 mg 12 Etodolac and Tolperisone Hcl Tablets 400 mg / 150 mg 13 Flupirtine Maleate Capsules 100 mg 14 Lornoxicam Tablets 4 mg 15 Lornoxicam Tablets 8 mg 16 Lornoxicam & Paracetamol Tablets 4 mg / 325 mg 17 Lornoxicam and Thiocolchicoside Tablets 8 mg / 4 mg 18 Lornoxicam and Thiocolchicoside Tablets 8 mg / 8 mg 19 Paracetamol Tablets 650 mg 20 Paracetamol Tablets 500 mg 21 Piroxicam Capsules 20 mg 22 Paracetamol and Thiocolchicoside Tablets 325 mg / 4 mg 23 Paracetamol and Thiocolchicoside Tablets 325 mg / 8 mg 24 Serratiopeptidase Tablets 10 mg 25 Thiocolchicoside Tablets 4 mg 26 Thiocolchicoside Tablets 8 mg 27 Thiocolchicoside and Etoricoxib Tablets 4 mg / 60 mg 28 Thiocolchicoside and Etoricoxib Tablets 8 mg / 60 mg 29 Tolperisone Hcl And Paracetamol Tablets 150mg / 325 mg 1 www.nanoceut.com ANALGESIC, NSAID, ANTISPASMODIC, ANTIINFLAMMATORY DRUGS SL.NO COMPOSITION STRENGTH 30 Tolperisone Hcl (SR) Tablets 450 mg 31 Tolperisone Hcl Tablets 50 mg 32 Tolperisone Hcl Tablets 100 mg 33 Tolperisone Hcl Tablets 150 mg 34 Tranexamic Acid and Mefenamic Acid Tablets 500 mg / 250 mg 35 Tramadol Hydrochloride Capsule 50 mg 36 Drotaverine and Aceclofenac Tablets 80 mg / 100 mg 37 Baclofen Tablets 20 mg 38 Baclofen Tablets 10 mg 39 Aceclofenac IP and Thiocolchicoside IP Tablets 100 mg / 4 mg Armour Units of 40 Trypsin-Chymotrypsin IP Tablets 100000AU enzymatic activity 41 Tramodol Hcl and Paracetamol Tablets 37.5 mg / 325 mg 42 Piroxicam Tablets 20 mg 43 Hyoscinebutylbromide I.P and Paracetamol I.P 10 mg / 325 mg 44 Hyoscinebutylbromide I.P 20 mg 45 Flavoxate Hcl Tablets 200 mg 46 Serrratiopeptidase I.P 5 mg 2 www.nanoceut.com ANTACID, ANTIEMETIC & GASTRIC DRUGS SL.NO COMPOSITION STRENGTH 1 Esomeprazole Magnesium Tablets 20 mg 2 Esomeprazole Magnesium Tablets 40 mg 3 Esomeprazole and Domperidone Capsules 40 mg / 30 mg 4 Lafutidine Tablets 5 mg 5 Lafutidine Tablets 10 mg 6 Lansoprazole Gastro-resistant Capsules 30 mg 7 Lansoprazole Gastro-resistant Capsules 15 mg 8 Omeprazole Magnesium Tablets 20 mg 9 Omeprazole and Domperidone Capsules 20 mg / 30 mg 10 Ondansetron Tablets 2 mg 11 Ondansetron Tablets 4 mg 12 Ondansetron Tablets 8 mg 13 Pantoprazole Tablets 20 mg 14 Pantoprazole Tablets 40 mg 15 Pantoprazole and Domperidone (SR) Capsules 40 mg / 20 mg 16 Pantoprazole and Itopride Capsules 40 mg / 150 mg 17 Rabeprazole Sodium Tablets 20 mg 18 Rabeprazole and Domperidone (sr) Capsules 20 mg / 30 mg 19 Ramosetron Hydrochloride Tablets 2.5 mcg 20 Ramosetron Hydrochloride Tablets 5 mcg 21 Rabeprazole and Itopride Capsules 20 mg / 150 mg 22 Sucralfate Tablets 1 gm 23 Ursodeoxycholic Acid IP Tablets 150 mg 24 Ursodeoxycholic Acid IP Tablets 300 mg 25 Levosulpiride and Rabeprazole Sodium Capsules 75 mg / 20 mg 26 Omeprazole and Domperidone Capsules 20 mg / 10 mg 27 Pantoprazole and Domperidone (SR) Capsules 40 mg / 30 mg 28 Cinitapride Hydrogen Tartrate (ER) 3 mg 29 Cinitapride Tablets 1 mg 1 www.nanoceut.com ANALGESIC, NSAID, ANTISPASMODIC, ANTIINFLAMMATORY DRUGS SL.NO COMPOSITION STRENGTH 30 Cinitapride Tablets 1 mg 31 Ilaprazole I.P 10 mg 2 www.nanoceut.com ANTI ALLERGIC & ANTI HISTAMINE DRUG SL.NO COMPOSITION STRENGTH 1 Acebrophylline Tablets 100 mg 2 Acebrophylline SR Tablets 200 mg 3 Ambroxol HCl and Desloratadine Capsules 75 mg / 5 mg 4 Ambroxol HCl and Levocetirizine Capsules 75 mg / 5 mg 5 Cetirizine Dihydrochloride Tablets 10 mg 6 Desloratadine Tablets 5 mg 7 Doxofylline and Salbutamol Tablets 400 mg / 2 mg 8 Doxofylline and Terbutaline Tablets 400 mg / 5 mg 9 Doxofylline Tablets 400 mg 10 Doxofylline and Ambroxol HCl Tablets 400 mg / 30 mg 11 Doxofylline and Montelukast Sodium Tablets 800 mg / 10 mg 12 Doxofylline and Montelukast Sodium Tablets 400 mg / 10 mg 13 Levocetirizine Dihydrochloride Tablets 5 mg 14 Levocetirizine Di HCl & Montelukast Sodium Tablets 2.5mg / 5 mg 15 Levocetirizine Di HCl & Ambroxol HCl Tablets 5 mg / 75 mg 16 Levocetirizine Di HCl, Ambroxol Hcl & Pseudoephedrine Capsules 5 mg / 75 mg / 120 mg 17 Montelukast Sodium Tablets 4 mg 18 Montelukast and Levocetirizine Tablets 10 mg / 5 mg 19 Montelukast and Levocetirizine Tablets 4 mg / 2.5 mg 20 Montelukast and Desloratadine Tablets 10 mg / 5 mg 21 Theophylline and Montelukast Tablets 400 mg / 10 mg 22 Cinnarizine Tablets 75 mg 23 Cinnarizine Tablets 25 mg 24 Fexofenadine Hydrochloride Tablets 120 mg 25 Fexofenadine Hydrochloride Tablets 180 mg 26 Fexofenadine And Montelukast Tablets 120mg / 10 mg 27 Montelukast Tablets IP 5 mg 28 Cetirizine and Ambroxol SR Tablets 10 mg / 75 mg 29 Flunarizine Tablets 5 mg 1 www.nanoceut.com ANTI ALLERGIC & ANTI HISTAMINE DRUG SL.NO COMPOSITION STRENGTH 30 Flunarizine Tablets 10 mg 31 Loratadine Tablets 10 mg 32 Uspambroxol Hcl and Desloratadine Capsules 75 mg / 5 mg 2 www.nanoceut.com ANTI BIOTICS DRUG SL.NO COMPOSITION STRENGTH 1 Amoxycillin Tablets 250 mg 2 Amoxycillin Capsules 250 mg 3 Amoxycillin Capsules 500 mg 4 Amoxycillin & Dicloxcillin Capsules 250 mg / 250 mg 5 Azithromycin Tablets 250 mg 6 Azithromycin Tablets 500 mg 7 Balooxacin Tablets 100 mg 8 Cexime And Dicloxacillin Tablets 200 mg / 500 mg 9 Cexime & L.acid Bacillus Tablets 200 mg / 2.5 Billion spores 10 Cephalexin Tablets IP 250 mg 11 Cephalexin Tablets IP 500 mg 12 Cefaclor Capsules IP 250 mg 13 Cephalexin Capsules IP 500 mg 14 Cephalexin Capsules IP 250 mg 15 Cloxacillin Capsules IP 250 mg 16 Doxycycline and L.bacillus Capsules 100 mg / 5 Billion spores 17 Cexime Trihydrate Dispersible Tablets 100 mg 18 Cefpodoxime Proxetil Tablets 200 mg 19 Cefpodoxime Proxetil Tablets 100 mg 20 Cefpodoxime Proxetil and Dicloxacillin Sodium Tablets 100mg / 500mg 21 Cefpodoxime Proxetil and Dicloxacillin Sodium Tablets 200mg / 500 mg 22 Cefuroxime Axetil Tablets 250mg 23 Cefuroxime Axetil Tablets 500mg 24 Cexime and Ooxacin Tablets 200 mg / 200 mg 25 Cexime and Ooxacin Tablets 100 mg / 100 mg 26 Cexime and Ooxacin Tablets 200 mg / 200 mg 27 Chloramphenicol Capsules 500 mg 28 Chloramphenicol Capsules 250 mg 29 Ciprooxacin Tablets 500 mg 1 www.nanoceut.com ANTI BIOTICS DRUG SL.NO COMPOSITION STRENGTH 30 Linezolid Tablets 600 mg 31 Levooxacin HCl Tablets 250 mg 32 Levooxacin HCl Tablets 500 mg 33 Ooxacin Dispersible Tablets 100 mg 34 Ooxacin Tablets 200 mg 35 Ooxacin and Ornidazole 200 mg / 500 mg 36 Clarithromycin IP Tablets 250 mg 37 Clarithromycin IP Tablets 500 mg 38 Clindamycin Capsules IP 150 mg 39 Ooxacin IP 400 mg 40 Ciprooxacin Hydrochloride IP 250 mg 41 Metronidazole Tablets 200 mg 2 www.nanoceut.com ANTI COLD DRUG SL.NO COMPOSITION STRENGTH 1 Paracetamol, Phenylephrine Hcl, Caffeine 500 mg / 5 mg (anhydrous) and Diphenhydramine Hcl Tablets / 30 mg / 25 mg 1 www.nanoceut.com ANTI DIABETIC DRUG SL.NO COMPOSITION STRENGTH 1 Glimepiride Tablets 1mg 2 Glimepiride Tablets 2mg 3 Glibenclamide and Metformin Hydrochloride Tablets 2.5mg / 500mg 4 Glimepiride, Pioglitazone and Metformin Hcl Tablets 1mg/15 mg/500mg 5 Glimepiride, Pioglitazone and Metformin Hcl Tablets 2 mg/15 mg/ 500 mg 6 Glimepiride and Metformin Hcl Tablets 1 mg / 1000 mg 7 Glimepiride and Metformin Hcl Tablets 2 mg / 1000 mg 8 Metformin Tablets 500 mg 9 Metformin Hcl Tablets 500 mg 10 Metformin Hcl Tablets 1000 mg 11 Voglibose Tablets 0.2 mg 12 Voglibose Tablets 0.3 mg 13 Voglibose & Metformin Hcl (SR) Tablets 0.2 mg / 500 mg 14 Voglibose & Metformin Hcl (SR) Tablets 0.3 mg / 500 mg 15 Glimepiride IP And Metformin Hcl IP Tablets 1 mg / 500 mg 16 Glimepiride IP And Metformin Hcl IP Tablets 2 mg / 500 mg 17 Gliclazide IP And Metformin Hcl IP Tablets 60 mg / 500 mg 18 Gliclazide IP And Metformin Hcl IP Tablets 80 mg / 500 mg 19 Voglibose IP And Metformin Hcl IP (SR) 0.2 mg / 500 mg 20 Telmisartan IP and Metoprolol Succinate (ER) 20 mg / 25 mg 21 Telmisartan IP and Metoprolol Succinate (ER) 40 mg / 50 mg 22 Gliclazide IP Tablets 40 mg 23 Gliclazide IP Tablets 60 mg 24 Gliclazide IP Tablets 80 mg 1 www.nanoceut.com DIURETIC DRUGS SL.NO COMPOSITION STRENGTH 1 Torsemide Tablets 5 mg 2 Torsemide Tablets 10 mg 3 Torsemide Tablets 20 mg 1 www.nanoceut.com ANTI FIBROTIC DRUG SL.NO COMPOSITION STRENGTH 1 Pirfenidone Tablets 200 mg 1 www.nanoceut.com ANTI FUNGAL DRUGS SL.NO COMPOSITION STRENGTH 1 Albendazole and Ivermectin Tablets 400 mg / 6mg 2 Fluconazole Tablets 150 mg 3 Ketoconazole Tablets 200 mg 4 Terbinane Hydrochloride USP Tablets 250 mg 5 Albendazole IP Tablets 400 mg 1 www.nanoceut.com ANTIMALARIAL DRUG SL.NO COMPOSITION STRENGTH 1 Artemether and Lumefantrine Tablets 40 mg / 240 mg 2 Artemether and Lumefantrine Tablets 80 mg / 480 mg 1 www.nanoceut.com ANTIVERTIGO & GABA DRUG SL.NO COMPOSITION STRENGTH 1 Betahistine Hydrochloride Tablets 8 mg 2 Betahistine Dihydrochloride Capsule 32 mg 3 Betahistine Dihydrochloride Capsule 48 mg 4 Betahistine Dihydrochloride Capsule 24 mg 5 Betahistine Hydrochloride Tablets 16 mg 6 Cabergoline Tablets 1 mg 7 Donepezil Hydrochloride Tablets 5 mg 8 Donepezil Hydrochloride Tablets 10 mg 9 Zolpidem Tartrate Tablets 5 mg 10 Zolpidem Tartrate Tablets 10 mg 11 Betahistine Hydrochloride IP Tablets 4 mg 1 www.nanoceut.com
Load more

Recommended publications
  • New Developments in Prokinetic Therapy for Gastric Motility Disorders
    REVIEW published: 24 August 2021 doi: 10.3389/fphar.2021.711500 New Developments in Prokinetic Therapy for Gastric Motility Disorders Michael Camilleri* and Jessica Atieh Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States Prokinetic agents amplify and coordinate the gastrointestinal muscular contractions to facilitate the transit of intra-luminal content. Following the institution of dietary recommendations, prokinetics are the first medications whose goal is to improve gastric emptying and relieve symptoms of gastroparesis. The recommended use of metoclopramide, the only currently approved medication for gastroparesis in the United States, is for a duration of less than 3 months, due to the risk of reversible or irreversible extrapyramidal tremors. Domperidone, a dopamine D2 receptor antagonist, is available for prescription through the FDA’s program for Expanded Access to Investigational Drugs. Macrolides are used off label and are associated with tachyphylaxis and variable duration of efficacy. Aprepitant relieves some symptoms of gastroparesis. There are newer agents in the pipeline targeting diverse gastric (fundic, antral and pyloric) motor functions, including novel serotonergic 5-HT4 agonists, dopaminergic D2/3 antagonists, neurokinin NK1 antagonists, and ghrelin agonist. Novel Edited by: targets with potential to improve gastric motor functions include the pylorus, macrophage/ Jan Tack, inflammatory function, oxidative
    [Show full text]
  • International Journal of Medicine and Pharmaceutical Research
    Wayal Sunil Anil et al, IJMPR, 2019, 7(6): 180-183 CODEN (USA): IJCPNH | ISSN: 2321-2624 International Journal of Medicine and Pharmaceutical Research Journal Home Page: www.pharmaresearchlibrary.com/ijmpr R E S E A R C H A R T I C L E Formulation and In-vitro Evaluation of Alosetron Oral Thin Films Wayal Sunil Anil1, G.S. Valluri2, Gampa Vijay Kumar3 Department of Pharmacy, KGR Institute of Technology and Management, Rampally, Kesara, Medchal, Telangana, India. A B S T R A C T Alosetron, is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome. In present study oral thin films of Alosetron were developed to have a faster on set of action. The oralthin films were developed by using polymers Guar gum, Pullulan and PVP K30.Oral thin films were prepared by employing solvent casting method. Propylene glycol was selected as permeation enhancer and plasticizer. Drug excipient compatibility studies were carried out by using FTIR, and it was observed that there were no interactions. Formulations were prepared with the varying concentrations polymers ranging from F1-F9, and all the formulations were evaluated for various physical parameters Physical appearance, Weight variation, Thickness, Folding endurance, Tensile strength, Drug content, Moisture uptake, Moisture content and all the results were found to be were found to be within the pharmacopeial limits, in-vitro drug release studies by using USP dissolution Apparatus Type II. Among all the 9 formulations F4 formulation which contain Pullulan 10mg and shown 97.06% cumulative drug release within 30 min.
    [Show full text]
  • Comprehensive Pgx Report for 1 / 31 Examples of Different Levels of Evidence for Pgx Snps
    Comprehensive PGx report for PERSONAL DETAILS Advanced Diagnostics Laboratory LLC CLIA:31D2149403 Phone: Fax: PATIENT DOB Address: 1030 North Kings Highway Suite 304 Cherry Hill, NJ 08034 GENDER FEMALE Website: http://advanceddiagnosticslaboratory.com/ SPECIMEN TYPE Oral Fluid LABORATORY INFORMATION ORDERING PHYSICIAN ACCESSION NUMBER 100344 FACILITY COLLECTION DATE 08/10/2020 RECEIVED DATE 08/14/2020 REPORT GENERATED 09/08/2020 LABORATORY DIRECTOR Dr. Jeanine Chiaffarano Current Patient Medication Clonidine (Catapres, Kapvay) The personalized pharmacogenomics profile of this patient reveals intermediate CYP2D6-mediated metabolism, extensive CYP1A2-mediated metabolism, and extensive CYP3A5-mediated metabolism. For further details, please find supporting evidence in this report or on websites such as www.pharmgkb.org or www.fda.gov. Losartan (Cozaar) The personalized pharmacogenomics profile of this patient reveals extensive CYP2C9-mediated metabolism, extensive CYP3A4-mediated metabolism, and extensive CYP3A5-mediated metabolism. For further details, please find supporting evidence in this report or on websites such as www.pharmgkb.org or www.fda.gov. Diltiazem (Cardizem, Tiazac) The personalized pharmacogenomics profile of this patient reveals extensive CYP3A4-mediated metabolism, intermediate CYP2C19-mediated metabolism, and extensive CYP3A5- mediated metabolism. For further details, please find supporting evidence in this report or on websites such as www.pharmgkb.org or www.fda.gov. Labetalol (Normodyne, Trandate) The personalized pharmacogenomics profile of this patient reveals intermediate CYP2D6-mediated metabolism, and intermediate CYP2C19-mediated metabolism. For further details, please find supporting evidence in this report or on websites such as www.pharmgkb.org or www.fda.gov. Mycophenolate mofetil (Myfortic, CellCept) The personalized pharmacogenomics profile of this patient reveals extensive CYP3A4-mediated metabolism, extensive CYP3A5-mediated metabolism, and extensive CYP2C8-mediated metabolism.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • List of Generic Medications
    List of Generic Medications D0001 3,4-methylenedioxy-methamphetamine (MDMA) D0031 Artemisinin D0002 Abacavir D0032 Artesunate D0003 Abiraterone D0033 Asenapine D0004 Acenocoumarol D0034 Aspirin D0005 Aclidinium D0035 Astemizole D0006 Albendazole D0036 Atazanavir D0007 Alfentanyl D0037 Atomoxetine D0008 Alfuzosin D0038 Atorvastatin D0009 Aliskiren D0039 Avanafil D0010 Allopurinol D0040 Axitinib D0011 Almotriptan D0041 Azathioprine D0012 Alogliptin D0042 Azilsartan D0013 Alosetron D0043 Bazedoxifene D0014 Alprazolam D0044 Bedaquiline D0015 Amantadine D0045 Bepridil D0016 Amiodarone D0046 Bicalutamide D0017 Amisulpride D0047 Bisoprolol D0018 Amitriptyline D0048 Boceprevir D0019 Amlodipine D0049 Bosentan D0020 Amobarbital D0050 Bosutinib D0021 Amodiaquine D0051 Brivaracetam D0022 Amoxapine D0052 Bromazepam D0023 Anastrozole D0053 Bromocriptine D0024 Apixaban D0054 Bromperidol D0025 Aprepitant D0055 Brotizolam D0026 Arformoterol D0056 Budesonide D0027 Aripiprazole D0057 Buprenorphine D0028 Armodafinil D0058 Bupropion D0029 Arteether D0059 Buspirone D0030 Artemether D0060 Cabozantinib [email protected] Page 1 List of Generic Medications D0061 Canagliflozin D0091 Clofarabine D0062 Cannabidiol (CBD) D0092 Clofibrate D0063 Cannabinol (CBN) D0093 Clomipramine D0064 Captopril D0094 Clonazepam D0065 Carbamazepine D0095 Clonidine D0066 Carisoprodol D0096 Clopidogrel D0067 Carmustine D0097 Clorazepate D0068 Carvedilol D0098 Clozapine D0069 Celecoxib D0099 Cocaine D0070 Ceritinib D0100 Codeine D0071 Cerivastatin D0101 Colchicine D0072 Cetirizine
    [Show full text]
  • A Four-Country Comparison of Healthcare Systems, Implementation
    Neurogastroenterology & Motility Neurogastroenterol Motil (2014) 26, 1368–1385 doi: 10.1111/nmo.12402 REVIEW ARTICLE A four-country comparison of healthcare systems, implementation of diagnostic criteria, and treatment availability for functional gastrointestinal disorders A report of the Rome Foundation Working Team on cross-cultural, multinational research M. SCHMULSON,* E. CORAZZIARI,† U. C. GHOSHAL,‡ S.-J. MYUNG,§ C. D. GERSON,¶ E. M. M. QUIGLEY,** K.-A. GWEE†† & A. D. SPERBER‡‡ *Laboratorio de Hıgado, Pancreas y Motilidad (HIPAM)-Department of Experimental Medicine, Faculty of Medicine-Universidad Nacional Autonoma de Mexico (UNAM). Hospital General de Mexico, Mexico City, Mexico †Gastroenterologia A, Department of Internal Medicine and Medical Specialties, University La Sapienza, Rome, Italy ‡Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Science, Lucknow, India §Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea ¶Division of Gastroenterology, Mount Sinai School of Medicine, New York, NY, USA **Division of Gastroenterology and Hepatology, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, USA ††Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore ‡‡Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel Key Messages • This report identified seven key issues related to healthcare provision that may impact how patients with FGIDs are investigated, diagnosed and managed. • Variations in healthcare provision around the world in patients with FGIDs have not been reviewed. • We compared four countries that are geographically and culturally diverse, and exhibit differences in the healthcare coverage provided to their population: Italy, South Korea, India and Mexico. • Since there is a paucity of publications relating to the issues covered in this report, some of the findings are based on the authors’ personal perspectives, press reports and other published sources.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • REVIEW Genotoxic and Carcinogenic Effects of Gastrointestinal Drugs
    Mutagenesis vol. 25 no. 4 pp. 315–326, 2010 doi:10.1093/mutage/geq025 Advance Access Publication 17 May 2010 REVIEW Genotoxic and carcinogenic effects of gastrointestinal drugs Giovanni Brambilla*, Francesca Mattioli and a further in vivo test using a tissue other than the bone marrow/ Antonietta Martelli peripheral blood should be done. Guidelines for carcinogenic- Department of Internal Medicine, Division of Clinical Pharmacology and ity testing of pharmaceuticals (4,5) indicate that a long-term Toxicology, University of Genoa, Viale Benedetto XV 2, I-16132 Genoa, Italy carcinogenicity study plus a short- or medium-term in vivo system should be performed for all pharmaceuticals whose expected clinical use is continuous for at least 6 months as *To whom correspondence should be addressed. Tel: +39 010 353 8800; well as for pharmaceuticals used frequently in an intermittent Fax: þ39 010 353 8232; Email: [email protected] manner in the treatment of chronic recurrent conditions. In the Received on January 28, 2010; revised on March 23, 2010; absence of clear evidence favouring one species, the rat should accepted on April 13, 2010 be selected. In long-term carcinogenicity assays, the highest This review provides a compendium of retrievable results dose should be at least .25-fold, on a milligram per square of genotoxicity and carcinogenicity assays performed on meter basis, than the maximum recommended human daily marketed gastrointestinal drugs. Of the 71 drugs consid- dose or represent a 25-fold ratio of rodent to human area under ered, 38 (53.5%) do not have retrievable data, whereas the curve. The maximum tolerated dose (MTD) or a limit dose the other 33 (46.5%) have at least one genotoxicity or of 2000 mg/kg can be used as alternatives.
    [Show full text]
  • Original Article
    ORIGINAL ARTICLE EFFICACY OF CINITAPRIDE HYDROGEN TARTARATE IN GERD Puneet Rijhwani1, C. M. Agarwal2, Mohammed Shoaib3, Prerna Upadhyaya4, Pradeep Agarwal5 HOW TO CITE THIS ARTICLE: Puneet Rijhwani, C. M. Agarwal, Mohammed Shoaib, Prerna Upadhyaya, Pradeep Agarwal. “Efficacy of Cinitapride Hydrogen Tartarate in GERD”. Journal of Evidence Based Medicine and Healthcare; Volume 1, Issue 8, October 15, 2014; Page: 1073-1079. ABSTRACT: BACKGROUND: Gastroesophageal reflux disease (GERD) is a chronic symptom of mucosal damage caused by stomach acid coming up from the stomach into the esophagus. Pathophysiological evidences point towards disordered motility as the main cause of GERD rather than acid hyper secretion. Cinitapride hydrogen tartrate is a 5-HT2-receptor antagonist and 5-HT4- receptor agonist activity. OBJECTIVE: The present study was planned to assess the efficacy and safety of Cinitapride hydrogen tartarate 1 mg tablets in gastro oesophageal reflux disease. MATERIAL AND METHODS: 35 adult patients (›20 years old), both genders from the outpatient clinic in private practices with diagnosis of gastroesophageal reflux were enrolled. One patient left the study due to an adverse reaction. 34 patients were analyzed. All patients received cinitapride 1 mg three times a day for four weeks. Patients were also supplied antacid tablets, which could be taken as a rescue medication during the course of the study. RESULTS: Total 29 male patients and 6 female patients enrolled in the study. There was a significant reduction in the mean overall symptoms intensity score from 8.4±1.4 (range: 6-11) at baseline to 0.3±1.1 (range: 0-6) at the end of week 4.
    [Show full text]
  • Elite Pgx Report
    Comprehensive PGx report for SANDRA HENRY PERSONAL DETAILS Redwood Lab Services LLC CLIA:45D2108203 Fax: PATIENT ENRY DOB 281-378-2116 281-466-2483 Address: 6776 Southwest Fwy Suite 600, Houston, TX 77074 GENDER Female Website: http://www.redwoodlabservices.com/ SPECIMEN TYPE Buccal Swab LABORATORY INFORMATION ORDERING PHYSICIAN - ACCESSION NUMBER 2006271582 FACILITY Elite Clinical Lab COLLECTION DATE 06/03/2020 RECEIVED DATE 07/01/2020 REPORT GENERATED 09/21/2020 LABORATORY DIRECTOR Chad Harper Current Patient Medication This patient is either not receiving any medication or may be receiving medications that are outside the scope of this report. A medication has potentially reduced ecacy, increased toxicity or the patient has a risk for the indicated condition. Guidelines exist for adjusting dosage, increased vigilance or the patient has risk for the indicated condition. The medication can be prescribed according to standard regimens or the patient's risk for the indicated condition is not increased. Comprehensive PGx report for SANDRA HENRY 1 / 29 G E NOTYP E /HAP L OTYP E /P HE NOTYP E DE TAIL Dis claimer: No patient should evaluate or use the information contained herein without the advice, consultation and supervision of a licensed healthcare professional such as a pharmacist or G ene G enotype-Haplotype P henotype physician. Laboratory-developed testing characteristics and protocols. R esults have not been reviewed or approved by the U.S . Food & Drug Administration (FDA). * This call was defaulted to the wild-type allele frequency because during review of the genotyping data, the genotype was C YP 1A2 *1A/*1A E xtensive metabolizer indeterminate.
    [Show full text]